blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3661929

EP3661929 - ISOCHROMAN COMPOUNDS AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.05.2022
Database last updated on 08.01.2025
FormerThe patent has been granted
Status updated on  11.06.2021
FormerGrant of patent is intended
Status updated on  11.03.2021
FormerRequest for examination was made
Status updated on  08.05.2020
FormerThe international publication has been made
Status updated on  09.02.2019
Formerunknown
Status updated on  29.08.2018
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Marlborough, MA 01752 / US
For all designated states
PGI Drug Discovery LLC
215 College Road
Paramus, NJ 07652 / US
[2020/24]
Inventor(s)01 / BOWEN, Carrie, A.
84 Waterford Drive
Marlborough, MA 01752 / US
02 / BURDI, Douglas, F.
84 Waterford Drive
Marlborough, MA 01752 / US
03 / HEFFERNAN, Michele, L., R.
84 Waterford Drive
Marlborough, MA 01752 / US
04 / HERMAN, Lee, W.
84 Waterford Drive
Marlborough, MA 01752 / US
05 / XIE, Linghong
84 Waterford Drive
Marlborough, MA 01752 / US
 [2020/24]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2020/24]Hoggett, Christopher James
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date18756100.601.08.2018
[2020/24]
WO2018US44854
Priority number, dateUS201762540249P02.08.2017         Original published format: US 201762540249 P
[2020/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019028165
Date:07.02.2019
Language:EN
[2019/06]
Type: A1 Application with search report 
No.:EP3661929
Date:10.06.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 07.02.2019 takes the place of the publication of the European patent application.
[2020/24]
Type: B1 Patent specification 
No.:EP3661929
Date:14.07.2021
Language:EN
[2021/28]
Search report(s)International search report - published on:EP07.02.2019
ClassificationIPC:C07D405/04, C07D413/04, C07D417/04, A61P25/08, A61K31/55
[2020/24]
CPC:
A61K31/352 (EP,EA,US); C07D405/04 (EP,EA,KR,US); A61K31/4155 (EP,EA,US);
A61K31/4178 (EP,EA,US); A61K31/42 (EP,EA,US); A61K31/422 (KR);
A61K31/427 (EP,EA,KR,US); A61K31/443 (EP,EA,US); A61K31/4433 (EP,EA,KR,US);
A61K31/497 (EP,EA,US); A61K31/506 (EP,EA,US); A61P25/00 (KR);
A61P25/08 (EP,EA,US); A61P25/16 (EP,EA,US); A61P25/24 (EP,EA,US);
A61P25/28 (EP,EA,KR,US); C07D413/04 (EP,EA,KR,US); C07D417/04 (EP,EA,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/24]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:ISOCHROMANVERBINDUNGEN UND VERWENDUNGEN DAVON[2020/24]
English:ISOCHROMAN COMPOUNDS AND USES THEREOF[2020/24]
French:COMPOSÉS D'ISOCHROMANE ET LEURS UTILISATIONS[2020/24]
Entry into regional phase06.02.2020National basic fee paid 
06.02.2020Designation fee(s) paid 
06.02.2020Examination fee paid 
Examination procedure06.02.2020Examination requested  [2020/24]
06.02.2020Date on which the examining division has become responsible
21.09.2020Amendment by applicant (claims and/or description)
12.03.2021Communication of intention to grant the patent
01.06.2021Fee for grant paid
01.06.2021Fee for publishing/printing paid
01.06.2021Receipt of the translation of the claim(s)
Opposition(s)19.04.2022No opposition filed within time limit [2022/25]
Fees paidRenewal fee
27.08.2020Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.08.2018
AL14.07.2021
AT14.07.2021
CY14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
IT14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
MK14.07.2021
MT14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SI14.07.2021
SK14.07.2021
SM14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
[2024/42]
Former [2024/23]HU01.08.2018
AL14.07.2021
AT14.07.2021
CY14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
IT14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
MK14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SI14.07.2021
SK14.07.2021
SM14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2023/33]HU01.08.2018
AL14.07.2021
AT14.07.2021
CY14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
IT14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SI14.07.2021
SK14.07.2021
SM14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2023/30]AL14.07.2021
AT14.07.2021
CY14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
IT14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SI14.07.2021
SK14.07.2021
SM14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2022/36]AL14.07.2021
AT14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
IT14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SI14.07.2021
SK14.07.2021
SM14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2022/29]AL14.07.2021
AT14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SI14.07.2021
SK14.07.2021
SM14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2022/25]AT14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SK14.07.2021
SM14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2022/24]AT14.07.2021
CZ14.07.2021
DK14.07.2021
EE14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
LT14.07.2021
LV14.07.2021
MC14.07.2021
NL14.07.2021
PL14.07.2021
RO14.07.2021
RS14.07.2021
SE14.07.2021
SK14.07.2021
LU01.08.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2022/21]AT14.07.2021
DK14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
LT14.07.2021
LV14.07.2021
NL14.07.2021
PL14.07.2021
RS14.07.2021
SE14.07.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2022/11]AT14.07.2021
ES14.07.2021
FI14.07.2021
HR14.07.2021
LT14.07.2021
LV14.07.2021
NL14.07.2021
PL14.07.2021
RS14.07.2021
SE14.07.2021
BG14.10.2021
NO14.10.2021
GR15.10.2021
IS14.11.2021
PT15.11.2021
Former [2022/09]AT14.07.2021
ES14.07.2021
FI14.07.2021
LT14.07.2021
NL14.07.2021
RS14.07.2021
SE14.07.2021
BG14.10.2021
NO14.10.2021
PT15.11.2021
Former [2022/08]AT14.07.2021
ES14.07.2021
FI14.07.2021
LT14.07.2021
NL14.07.2021
SE14.07.2021
BG14.10.2021
NO14.10.2021
Former [2022/07]AT14.07.2021
LT14.07.2021
NL14.07.2021
NO14.10.2021
Cited inInternational search[A]US4500543  (DEBERNARDIS JOHN F [US], et al) [A] 1-69* Column 1, lines 7-9; claim 1. *;
 [A]US4994486  (SCHOENLEBER ROBERT W [US], et al) [A] 1-69 * Abstract; claims; examples; column 74, lines 11-13: intermediate of step 9. *;
 [A]US6235774  (FAHRIG THOMAS [DE], et al) [A] 1-69 * Abstract; claims 1; examples. *;
 [AP]WO2018023072  (SUNOVION PHARMACEUTICALS INC [US]) [AP] 1-69 * Abstract; claims; examples. *
by applicant   - BLUME et al., Epilepsia, (20010000), vol. 42, pages 1212 - 1218
    - FISHER et al., Epilepsia, vol. 46, no. 4, pages 470 - 2
    - HAUSER et al., Epilepsia, (19910000), vol. 32, pages 429 - 445
    - BEGLEY et al., Epilepsia, (19940000), vol. 35, pages 1230 - 1243
    - FOSTER, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., (19840000), vol. 5, no. 12, doi:doi:10.1016/0165-6147(84)90534-0, pages 524 - 527, XP025943358

DOI:   http://dx.doi.org/10.1016/0165-6147(84)90534-0
    - MAEHR, J. Chem. Ed., (19850000), vol. 62, pages 114 - 120
    - S. M. BERGE et al., "pharmaceutically acceptable salts", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
    - M. E. BARTON et al., Epilepsy Research, (20010000), vol. 47, pages 217 - 227
    - DUVEAU, V. et al., CNS Neuroscience & Therapeutics, (20160000), vol. 22, pages 497 - 506
    - S.L. ROBERDS et al., Front. Neurosci., (20110909), vol. 5, page 103
    - D. BRUNNER et al., Drug Discov. Today, (20020000), vol. 7, pages S107 - S112
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.